421 related articles for article (PubMed ID: 22147714)
1. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.
Nayak S; Roberts MS; Greenspan SL
Ann Intern Med; 2011 Dec; 155(11):751-61. PubMed ID: 22147714
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Virtual Bone Strength Testing in Osteoporosis Screening Programs for Postmenopausal Women in the United States.
Agten CA; Ramme AJ; Kang S; Honig S; Chang G
Radiology; 2017 Nov; 285(2):506-517. PubMed ID: 28613988
[TBL] [Abstract][Full Text] [Related]
3. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
Yoshimura M; Moriwaki K; Noto S; Takiguchi T
Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
Mueller D; Gandjour A
Appl Health Econ Health Policy; 2008; 6(2-3):113-35. PubMed ID: 19231905
[TBL] [Abstract][Full Text] [Related]
5. Screening for osteoporosis in Chinese post-menopausal women: a health economic modelling study.
Si L; Winzenberg TM; Chen M; Jiang Q; Neil A; Palmer AJ
Osteoporos Int; 2016 Jul; 27(7):2259-2269. PubMed ID: 26815042
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry.
Ito K; Leslie WD
Osteoporos Int; 2015 Aug; 26(8):2111-9. PubMed ID: 25807913
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
[TBL] [Abstract][Full Text] [Related]
8. Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?
Yang J; Cosman F; Stone PW; Li M; Nieves JW
Osteoporos Int; 2020 Dec; 31(12):2321-2335. PubMed ID: 32778935
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis.
Marín F; López-Bastida J; Díez-Pérez A; Sacristán JA;
Calcif Tissue Int; 2004 Mar; 74(3):277-83. PubMed ID: 14708042
[TBL] [Abstract][Full Text] [Related]
10. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.
Ito K
JAMA Netw Open; 2020 Dec; 3(12):e2027584. PubMed ID: 33258906
[TBL] [Abstract][Full Text] [Related]
12. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
Schwenkglenks M; Lippuner K
Osteoporos Int; 2007 Nov; 18(11):1481-91. PubMed ID: 17530156
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
Mueller D; Gandjour A
Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
[TBL] [Abstract][Full Text] [Related]
14. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 Feb; 28(2):585-595. PubMed ID: 27726000
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Moriwaki K; Fukuda H
Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
[TBL] [Abstract][Full Text] [Related]
17. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
18. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment.
Nayak S; Roberts MS; Greenspan SL
PLoS One; 2012; 7(3):e32879. PubMed ID: 22427903
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
